ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies
Sessions Highlight Off-The-Shelf, CRISPR Approaches
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
You may also be interested in...
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.